Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 10/20 | 0.58 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15554730 | 1.00 | SLC16A3 (0.58) | SLC16A3FOLH1TSHRMAPK1CYP2C9 | |
| SCHEMBL4599890 | 0.98 | FOLH1 (0.56) | SLC16A3FOLH1TSHRMAPK1CYP2C9 | |
| SCHEMBL4703927 | 0.95 | FOLH1 (0.56) | SLC16A3FOLH1TSHRMAPK1CYP2C9 | |
| SCHEMBL13313199 | 0.89 | LMNA (0.49) | SLC16A3FOLH1TSHR | |
| SCHEMBL8245934 | 0.88 | FOLH1 (0.59) | SLC16A3FOLH1TSHRMAPK1CYP2C9 | |
| SCHEMBL9345842 | 0.88 | FOLH1 (0.68) | SLC16A3FOLH1TSHR | |
| SCHEMBL13313177 | 0.87 | LMNA (0.50) | SLC16A3FOLH1TSHR | |
| SCHEMBL9011058 | 0.86 | PPARA (0.52) | SLC16A3FOLH1PPARA | |
| SCHEMBL729909 | 0.86 | FOLH1 (0.70) | SLC16A3FOLH1TSHR | |
| SCHEMBL586009 | 0.83 | BID (0.59) | SLC16A3FOLH1TSHRPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1737 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3606528-B1 | TRICYCLIC COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 (GSK3) INHIBITORS AND USES THEREOF | BROAD INST INC (US) | 2023-10-18 | — | — | EP | claimed |
| EP-3649135-B1 | SYNTHESIS OF HALICHONDRINS | HARVARD COLLEGE (US) | 2022-12-28 | — | — | EP | claimed |
| US-11241435-B2 | Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis | THE GENERAL HOSPITAL CORPORATION (US) | 2022-02-08 | — | — | US | claimed |
| EP-3172213-B1 | MACROCYCLIC KINASE INHIBITORS AND USES THEREOF | DANA FARBER CANCER INST INC (US) | 2021-09-22 | — | — | EP | claimed |
| EP-3092220-B1 | VITAMIN C PRODRUGS AND USES THEREOF | UNIV FLORIDA (US) | 2021-01-20 | — | — | EP | claimed |
| US-10870651-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-12-22 | — | — | US | claimed |
| EP-3171874-B1 | IMIDAZOLYL KINASE INHIBITORS AND USES THEREOF | DANA FARBER CANCER INST INC (US) | 2020-11-18 | — | — | EP | claimed |
| US-9856225-B2 | Substituted phenazines as antimicrobial agents | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2018-01-02 | — | — | US | claimed |
| US-12042513-B2 | Proteolysis targeting chimeric molecules (PROTACs) with functional handles and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2024-07-18 | — | — | US | disclosed |
| WO-2024151519-A2 | PPARG MODULATORS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATIN, INCORPORATED (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20240226302-A1 | BIODEGRADABLE LIPIDS AND FORMULATIONS FOR INTRAMUSCULAR, IN VITRO, AND EX VIVO TRANSFECTION OF MRNA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228671-A1 | POLYPEPTIDYL LINKERS | Quantum-Si Incorporated (US) | 2024-07-11 | — | — | US | disclosed |
| WO-2013006758-A1 | DIPHOSPHATE MIMETICS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-01-10 | — | — | WO | disclosed |
| WO-2013003315-A2 | METHODS FOR PREPARING ISOQUINOLINES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-01-03 | — | — | WO | disclosed |
| WO-2012167021-A2 | HYPERFORIN ANALOGS, METHODS OF SYNTHESIS, AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-12-06 | — | — | WO | disclosed |
| WO-2012135615-A2 | ENOPEPTINS, USES THEREOF, AND METHODS OF SYNTHESIS THERETO | BROWN UNIVERSITY (US) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012016186-A1 | MACROCYCLIC KINASE INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-02-02 | — | — | WO | disclosed |
| WO-2012006104-A2 | COMPOUNDS AND METHODS FOR TREATING TUBERCULOSIS INFECTION | Academia Sinica, Taiwan (TW) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226302-A1 | BIODEGRADABLE LIPIDS AND FORMULATIONS FOR INTRAMUSCULAR, IN VITRO, AND EX VIVO TRANSFECTION OF MRNA | CPT1B, IGF2BP2, IGF2BP3 | SLC16A3 282/4885FOLH1 4386/4885TSHR 1434/4885 |
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | UACA, ADCYAP1R1, ADCY1 | SLC16A3 1469/4885FOLH1 858/4885TSHR 1060/4885 |
| US-20240228671-A1 | POLYPEPTIDYL LINKERS | VIP, DNPEP, PREP | SLC16A3 855/4885FOLH1 26/4885TSHR 3267/4885 |
| US-11241435-B2 | Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis | SOST, SIK2, SIK1 | SLC16A3 2797/4885FOLH1 3957/4885TSHR 1825/4885 |
| US-10870651-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK7, CDK3, CDK9 | SLC16A3 1433/4885FOLH1 4506/4885TSHR 3533/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | SLC16A3 1387/4885FOLH1 2099/4885TSHR 728/4885 |
| US-12042513-B2 | Proteolysis targeting chimeric molecules (PROTACs) with functional handles and uses thereof | CRBN, PSMA6, PSMA3 | SLC16A3 4654/4885FOLH1 627/4885TSHR 3065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.